ArticleFrontiers in medicine2026
Cluster analysis and risk prediction model construction for antisynthase syndrome-associated interstitial lung disease based on clinical, imaging, and antibody characteristics.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Distinct phenotypic clusters associated with progressive pulmonary fibrosis in anti-synthetase syndrome-associated interstitial lung disease.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Interstitial lung disease (ILD) is a common and serious complication of anti-synthase syndrome (ASS), exhibiting high heterogeneity. This study aimed to stratify patients with ASS-associated ILD (ASS-ILD) based on their clinical features, high-resolution computed tomography (HRCT) findings, and specific antibody profiles. We also aimed to build a predictive model for severe ASS-ILD to help identify it more accurately. Methods: We retrospectively analyzed the clinical and laboratory data of 100 patients with ASS-ILD. Unsupervised clustering of clinical characteristics was done using multiple correspondence analysis (MCA) and hierarchical cluster analysis. Univariate and multivariate logistic regression were used to find independent risk factors for severe ASS-ILD, and a risk prediction model was built. Results: We identified three patient groups: Cluster 1 ( Conclusion: Identifying ASS-ILD heterogeneity requires comprehensive consideration of HRCT features, antibody profiles, and clinical manifestations. The combined biomarker index (based on complement C3, rash, and age) offers an objective tool for ASS-ILD diagnosis and risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.